Harrow, Inc. (HROW) 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2024. Harrow, Inc. is a leading eyecare pharmaceutical company operating two primary segments: Branded (FDA-approved ophthalmic products) and ImprimisRx (ophthalmology-focused pharmaceutical compounding). The company markets a portfolio of branded products including IHEEZO, VEVYE, and TRIESENCE, and operates compounding facilities in New Jersey under Sections 503A and 503B of the FDCA.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenues | $199.6 million | $130.2 million |
| Gross Profit | $150.4 million | $90.6 million |
| Net Loss | $(17.5) million | $(24.4) million |
| Income from Operations | $8.8 million | $0.4 million |
| Cash and Cash Equivalents (Year End) | $47.2 million | $74.1 million |
| Total Debt (Principal) | $226.5 million | $195.5 million |
| Accumulated Deficit | $(151.4) million | $(133.9) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 53% to $199.6 million, driven by a 131% surge in Branded revenue ($116.1 million) due to the launch of VEVYE and increased sales of IHEEZO. ImprimisRx revenue grew modestly by 4% to $83.5 million.
- Profitability: The company narrowed its net loss by $6.9 million year-over-year, primarily due to higher gross margins and improved operating income, despite increased operating expenses.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses rose 55% to $129.1 million, attributed to sales force expansion for VEVYE and regulatory costs. R&D expenses nearly doubled to $12.2 million, including $2.0 million in one-time costs for TRIESENCE development.
- Debt Activity: The company drew an additional $30.0 million under its Oaktree Loan facility in October 2024 to fund a $37.0 million milestone payment to Novartis for the commercial availability of TRIESENCE. Total principal debt outstanding reached $226.5 million.
- Investment Exit: The company sold its entire equity interest in Eton Pharmaceuticals in April 2024, recognizing a loss of $3.2 million.
Guidance, Outlook, Risks, and Unusual Items
- Liquidity and Going Concern: The Oaktree Loan matures in January 2026 with a principal balance of $107.5 million. Management states there is "substantial doubt" about the ability to continue as a going concern without refinancing. Discussions with lenders are ongoing, but no assurance of refinancing terms is provided.
- Regulatory Risks (FDA): The company's New Jersey outsourcing facility (NJOF) received a Form 483 with five observations during a 2024 FDA inspection. The company voluntarily recalled certain products and is engaged in ongoing remediation and discussions with the FDA. Failure to demonstrate compliance could lead to enforcement actions.
- Cybersecurity Incident: In November 2024, a cybersecurity incident involving unauthorized email access resulted in the fraudulent diversion of company funds. The company recorded a loss of $271,000 and believes the financial impact was minimized due to early detection.
- Legal Proceedings: In November 2024, a jury awarded Harrow $34.9 million in damages against Ocular Science, Inc. (OSRX) for trademark infringement. Due to uncertainty regarding collection, no gain was recorded in 2024 financials.
- Strategic Initiatives: The company launched "Project Beagle" to transition ImprimisRx patients from compounded formulations to FDA-approved Harrow products (e.g., transitioning from Klarity-C to VEVYE).
Investor Verification Checklist
- Debt Refinancing Status: Verify the progress of refinancing discussions for the $107.5 million Oaktree Loan maturing in January 2026.
- FDA Compliance Resolution: Monitor updates regarding the resolution of the 2024 Form 483 observations at the NJOF facility and any potential enforcement actions.
- Collection of Legal Award: Track the status of collecting the $34.9 million jury verdict against OSRX.
- Product Transition Impact: Assess the financial impact of "Project Beagle" on ImprimisRx revenue as compounded products are replaced by branded alternatives.
- Cash Burn Rate: Review quarterly cash flow statements to ensure the $47.2 million cash balance is sufficient to cover operations and interest payments until refinancing is secured.